Business
Imfinzi approved in US for biliary tract cancer
Imfinzi approved in US for biliary tract cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n 5 September 2022 07:00 BST\n \n \n \n \n \n \n Imfinzi\n \n \n plus chemotherapy approved in the US as the first immunotherapy regimen for patients with advanced biliary tract cancer\n \n \n \n \n \n \n Approval based on TOPAZ-1 Phase III trial results, which showed Imfinzi\n \n \n combination reduced risk of death by 20% vs. chemotherapy alone\n \n \n \n \n \n AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).\n \n \n \n \n \n The approval by the Food and Drug Administration (FDA) was based on the results from the\n \n TOPAZ-1 Phase III trial\n \n . In an interim analysis of TOPAZ-1, Imfinzi plus chemotherapy reduced the risk of death by 20% versus chemotherapy alone (hazard ratio [HR] 0.80; 95% confidence interval [CI] 0.66-0.97; p=0.021). An estimated one in four (25%) patients treated with Imfinzi plus chemotherapy were still alive at two years compared to one in 10 (10%) treated with chemotherapy alone. Results were consistent across all prespecified subgroups, regardless of PD-L1 expression or tumour location.\n \n \n \n \n \n BTC is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder.1,2 Approximately 23,000 people in the US are diagnosed with BTC each year.1 These patients have a poor prognosis, with approximately 5% to 15% of patients with BTC surviving five years.3\n \n \n \n \n \n Aiwu Ruth He, MD, PhD, Associate Professor of Medicine, Leader of the GI Cancer Program, Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington DC, and a lead investigator in the TOPAZ-1 Phase III trial, said: \"This approval represents a major step forward for patients with advanced biliary tract cancer, who urgently need new, well-tolerated and effective treatment options after more than a decade of limited innovation. The combination of durvalumab and chemotherapy should become a new standard of care in this setting, having demonstrated significantly improved survival for these patients who have historically faced a poor prognosis.\"\n \n \n \n \n \n Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: \"For ...